Long-term safety of ML-007C-MA for hallucinations and delusions in Alzheimer's disease
Tests ML-007C-MA over 52 weeks in adults with Alzheimer's disease psychosis.
Plain-language title generated from the registry record
Registry title: An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Key facts
- Where
- Vranov nad Topľou, SlovakiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 91 years old?
- Has a doctor told you that you have Alzheimer's disease?
- Do you have hallucinations or delusions caused by Alzheimer's disease?
- Have you taken part in an earlier study of the same medicine (KarXT or ML-007C-MA) and finished it?
Source: NCT07459660, who can take part
Where in Slovakia
- Crystal Comfort S.R.O.Vranov nad Topľou, SlovakiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- MapLight Therapeutics
- Trial code
- NCT07459660EU 2025-521757-16-00
- Record updated
- 7 August 2026
- Original description
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).Read full original descriptionShow less
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
Inclusion: Willing and able to provide written informed consent, or, if deemed lacking in the capacity to provide informed consent, the following requirements for consent must be met:; The participant's LAR must provide written informed consent. AND; The participant will provide informed assent; Has completed the Double-Blind Treatment Period of an antecedent study with ML-007C-MA (ie, ML-007C-MA-221); May benefit from long-term therapy with open-label ML-007C-MA treatment, in the judgment of the investigator; Has a designated study care partner who is in contact with the participant frequently enough to accurately report on the participant's symptoms and adherence to study drug; Resides in a stable living environment (eg, home, residential assisted living, or nursing home facility) and is expected to remain in the living situation throughout the study.
Exclusion: Under the care of hospice, bed-bound, or receiving end-of-life palliative care; Requires treatment with protocol-defined prohibited medications; Has developed an allergy or other intolerance to ML-007C-MA, its active ingredients or their excipients since the antecedent study; Has or had a clinically significant abnormal physical examination, vital sign, ECG or clinical laboratory safety result during or since the antecedent study that would compromise participant safety, interfere with the participant's ability to comply with study procedures, and/or would confound the interpretation of the outcome measures in the study in the opinion of the investigator; Has developed a new or worsening medical comorbidity during or since the antecedent study that, in the opinion of the investigator and/or medical monitor, would compromise participant safety, interfere with the participant's ability to comply with study procedures, would preclude obtaining voluntary consent/assent, and/or would substantially impair the evaluation of study assessments; Has an elevated risk of suicidal behavior.